Valneva Reports Positive Results for Phase 1 Trial of Second-Generation Zika Vaccine Candidate
Valneva Reports Positive Results for Phase 1 Trial of Second-Generation Zika Vaccine Candidate GlobeNewswire November 04, 2025 Immune response successfully improved with second generation vaccine candidate Saint-Herblain (France), November 4, 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced positive results of its Phase 1 clinical trial investigating the […]